Istiratumab (MM-141) is an experimental monoclonal antibody for the treatment of cancer. It is a bispecific antibody targeting IGF-1R and ErbB3.
It is in development by Merrimack Pharmaceuticals (In the US) and was awarded orphan drug status for pancreatic cancer.